TRGT
Targacept Inc
Clinical-stage biopharmaceutical company developing neuronal nicotinic receptor (NNR) modulators to treat central nervous system diseases and disorders
CUSIP: 87611R306HealthcareUS1 holder
Targacept Inc
Clinical-stage biopharmaceutical company developing neuronal nicotinic receptor (NNR) modulators to treat central nervous system diseases and disorders
No financial data available for this security.